Arcturus Therapeutics (ARCT) Expected to Announce Quarterly Earnings on Thursday

Arcturus Therapeutics (NASDAQ:ARCT) will likely be issuing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.0133) per share and revenue of $6.2960 million for the quarter. Parties may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.92) by ($0.11). The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $14.32 million. Arcturus Therapeutics had a negative return on equity of 29.13% and a negative net margin of 80.19%. On average, analysts expect Arcturus Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arcturus Therapeutics Stock Down 1.9%

NASDAQ:ARCT opened at $8.41 on Wednesday. The firm has a market capitalization of $239.01 million, a price-to-earnings ratio of -3.53 and a beta of 2.43. Arcturus Therapeutics has a twelve month low of $5.85 and a twelve month high of $24.17. The stock’s 50 day moving average price is $7.84 and its two-hundred day moving average price is $8.01.

Wall Street Analyst Weigh In

ARCT has been the topic of several recent analyst reports. Roth Mkm started coverage on Arcturus Therapeutics in a research report on Thursday, January 22nd. They set a “buy” rating and a $20.00 price target on the stock. Citigroup reduced their target price on Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Weiss Ratings upgraded Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, April 21st. B. Riley Financial started coverage on Arcturus Therapeutics in a research note on Wednesday, March 18th. They set a “buy” rating and a $22.00 target price for the company. Finally, Piper Sandler reduced their target price on Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Arcturus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

Institutional Trading of Arcturus Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. boosted its stake in Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares during the period. BNP Paribas Financial Markets raised its holdings in Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in Arcturus Therapeutics in the 4th quarter valued at $64,000. Intech Investment Management LLC acquired a new position in Arcturus Therapeutics in the 4th quarter valued at $70,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in Arcturus Therapeutics by 65.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock valued at $73,000 after acquiring an additional 4,737 shares in the last quarter. 94.54% of the stock is currently owned by institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.